Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers | Zendy

Michael R. Sargen | Zendy; Hildur Helgadóttir | Zendy; Xiaohong R. Yang | Zendy; Mark Harland | Zendy; Jessica N. Hatton | Zendy; Kristine Jones | Zendy; Belynda Hicks | Zendy; Amy Hutchinson | Zendy; Michael Curry | Zendy; Margaret A. Tucker | Zendy; Alisa M. Goldstein | Zendy; Ruth M. Pfeiffer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers

Author(s) -

Michael R. Sargen,

Hildur Helgadóttir,

Xiaohong R. Yang,

Mark Harland,

Jessica N. Hatton,

Kristine Jones,

Belynda Hicks,

Amy Hutchinson,

Michael Curry,

Margaret A. Tucker,

Alisa M. Goldstein,

Ruth M. Pfeiffer

Publication year - 2022

Publication title -

jnci cancer spectrum

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.345

H-Index - 10

ISSN - 2515-5091

DOI - 10.1093/jncics/pkac074

Subject(s) - medicine , cdkn2a , p14arf , cancer , oncology , population , cancer registry , cumulative incidence , skin cancer , incidence (geometry) , lung cancer , pancreatic cancer , melanoma , gastroenterology , cohort , carcinogenesis , cancer research , tumor suppressor gene , physics , environmental health , optics

Few studies have evaluated the relationship between CDKN2A germline pathogenic variants (GPV), transcript (p16/p14ARF) alteration, and cancer risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research